Olmesartan/Amlodipin/Hct Ratiopharm

Olmesartan medoxil, Hydrochlorothiazide, Amlodipine besilate, the active ingredients in Olmesartan/Amlodipin/Hct Ratiopharm, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure, often in patients who require more than one mechanism to achieve target blood pressure control.

GNH USA supplies Olmesartan/Amlodipin/Hct Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipin/Hct Ratiopharm is used in the management of hypertension, acting on several pathways that regulate vascular tone and fluid balance. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Resistant hypertension: provides additional blood pressure reduction when monotherapy is insufficient. - Hypertensive patients with edema: counteracts calcium‑channel blocker‑induced peripheral edema. - Hypertension with concomitant fluid retention: promotes natriuresis and diuresis to aid blood pressure control.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Cough

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Electrolyte disturbances (e.g., hyponatremia, hyperkalemia) - Angio‑edema - Liver enzyme elevations - Pancreatitis

When prescribing this combination, clinicians should consider several safety aspects. - Renal function: assess baseline creatinine and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially with diuretic component. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: avoid use during pregnancy due to fetal risk. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipin/Hct Ratiopharm may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): may cause excessive potassium loss and renal dysfunction. - Potassium‑saving diuretics or supplements: increase risk of hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise amlodipine plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: can increase lithium concentrations, risking toxicity. - Other antihypertensives: may cause additive blood pressure lowering. - Antacids containing aluminium or magnesium: may reduce absorption of olmesartan.